Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

Diffuse Diabetic Macular Edema Clinical Trial

Status Withdrawn

Clinical Trial Summary

Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00600301
Study type	Interventional
Source	Asociación para Evitar la Ceguera en México
Contact
Status	Withdrawn
Phase	Phase 3
Start date	January 2008
Completion date	January 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00571142` - Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema	Phase 3
Withdrawn	`NCT00567372` - POSTERIOR SUB-TENON'S Avastin	Phase 4
Recruiting	`NCT00999791` - Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema	Phase 1
Completed	`NCT00886808` - Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema	Phase 1
Recruiting	`NCT01218750` - Triple Therapy for Diffuse Diabetic Macular Edema	N/A